The Pfizer pharmaceutical announced that his vaccine against COVID-19 it is 95% effective from 28 days after the first dose, according to a statement from the company itself, which already issued a first efficacy evaluation a few days ago.
According to the statement, in this latest evaluation of phase three 170 confirmed cases of COVID-19 have been identified, of which 162 were detected in the placebo group compared to 8 in those who received the vaccine. In total, more than 41,000 people have participated in this trial around the world.
“The efficacy was constant according to age, gender, race and ethnicity,” says the company statement, which highlights that “the efficacy observed in adults over 65 years was greater than 94%.”
(Information from EFE – We will expand shortly)
How to face the problem of public health in a country? – Vital space
In the framework of the elections in the United States, Dr. Elmer Huerta wonders how to face the problem of public health in a country? He explained that the president should surround himself with technicians who evaluate and detect health problems. With this, they develop and approve control strategies for the population.